Gene therapy has come a long way in the last decade, with multiple recent approvals. Our iCELLis™ bioreactors are used in several of these commercial processes for viral vector manufacturing. The industry hasn’t remained static; neither has the technology we design to help trailblazers bring life-changing medicines to patients faster.
In this webinar, AGC Biologics discusses their journey to successful implementation and how they’ve used this technology to build and support their new BravoAAV™ and ProntoLVV™ vector platforms.
Watch now to:
- Learn the methodologies for generating reliable process charts for lentivirus and AAV productions.
- Enhance virus productivity by upscaling with the iCELLis bioreactor systems.
- Evaluate product quality by measuring potency and impurities profiles.
